SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

May 19, 2026

Study Completion Date

October 24, 2026

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

SG301 SC Injection

Subcutaneous injection every two weeks

DRUG

SG301 SC Placebo

Subcutaneous injection every two weeks

Trial Locations (10)

200040

RECRUITING

Huashan Hospital affiliated to Fudan University, Shanghai

233000

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250063

RECRUITING

Shandong University Qilu Hospital, Jinan

272002

RECRUITING

Jining First People's Hospital, Jining

314408

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

330006

RECRUITING

Jiangxi Provincial People's Hospital, Nanchang

337099

RECRUITING

Pingxiang People's Hospital, Pingxiang

350004

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

361003

RECRUITING

First Affiliated Hospital of Xiamen University, Xiamen

518020

RECRUITING

Shenzhen People's Hospital, Shenzhen

All Listed Sponsors
lead

Hangzhou Sumgen Biotech Co., Ltd.

INDUSTRY